Naji C Salloum1, Maurizio Fava2, Rebecca S Hock3, Marlene P Freeman2, Martina Flynn2, Bettina Hoeppner3, Cristina Cusin3, Dan V Iosifescu4, Madhukar H Trivedi5, Gerard Sanacora6, Sanjay J Mathew7, Charles Debattista8, Dawn F Ionescu3, George I Papakostas2. 1. Massachusetts General Hospital, Harvard Medical School, USA; Clinical Trials Network and Institute, Massachusetts General Hospital, USA. Electronic address: nchaayasalloum@mgh.harvard.edu. 2. Massachusetts General Hospital, Harvard Medical School, USA; Clinical Trials Network and Institute, Massachusetts General Hospital, USA. 3. Massachusetts General Hospital, Harvard Medical School, USA. 4. New York University School of Medicine, Nathan Kline Institute, USA. 5. The University of Texas Southwestern Medical Center, USA. 6. Yale School of Medicine, USA. 7. Baylor College of Medicine and Michael E. Debakey VA Medical Center, Houston, TX, USA. 8. Stanford University School of Medicine, USA.
Abstract
OBJECTIVE: To examine the rate and time to relapse for remitters and responders to ketamine in treatment-resistant depression (TRD). METHODS:Subjects with TRD were randomized to a single infusion of one of several doses of intravenous ketamine, or midazolam. Using Kaplan-Meier survival function, the current report examines the rate and time to relapse, defined as MADRS ≥ 22, over a period of 30 days, in subjects who achieved remission (MADRS ≤ 10) or response (≥ 50% reduction in MADRS) on day three post-infusion of intravenous ketamine 0.1, 0.5, or 1.0 mg/kg. RESULTS: Of the 60 randomized participants who received a single ketamine (0.1, 0.5, or 1.0 mg/kg) infusion, 19 (34%) met criteria for remission and 27 (48%) for response, on day 3 post-infusion. A numerical dose-response relationship was observed, with remitters/responders on ketamine 1.0 mg/kg having the lowest relapse rate, followed by ketamine 0.5 mg/kg and 0.1 mg/kg, respectively (% of remitters who relapsed by day 14: 38% with 1.0 mg/kg, 50% with 0.5 mg/kg, 100% with 0.1 mg/kg;% of responders who relapsed by day 14: 30% with 1.0 mg/kg, 50% with 0.5 mg/kg, 80% with 0.1 mg/kg). LIMITATIONS: The sample size was small. No MADRS measurements at day one post-infusion. The study was not powered to assess differences in relapse prevention between different doses of ketamine. CONCLUSION: Time to relapse after successful treatment with a single infusion of ketamine appears to follow a dose-response relationship, where higher dosage leads to increased time to relapse.
RCT Entities:
OBJECTIVE: To examine the rate and time to relapse for remitters and responders to ketamine in treatment-resistant depression (TRD). METHODS: Subjects with TRD were randomized to a single infusion of one of several doses of intravenous ketamine, or midazolam. Using Kaplan-Meier survival function, the current report examines the rate and time to relapse, defined as MADRS ≥ 22, over a period of 30 days, in subjects who achieved remission (MADRS ≤ 10) or response (≥ 50% reduction in MADRS) on day three post-infusion of intravenous ketamine 0.1, 0.5, or 1.0 mg/kg. RESULTS: Of the 60 randomized participants who received a single ketamine (0.1, 0.5, or 1.0 mg/kg) infusion, 19 (34%) met criteria for remission and 27 (48%) for response, on day 3 post-infusion. A numerical dose-response relationship was observed, with remitters/responders on ketamine 1.0 mg/kg having the lowest relapse rate, followed by ketamine 0.5 mg/kg and 0.1 mg/kg, respectively (% of remitters who relapsed by day 14: 38% with 1.0 mg/kg, 50% with 0.5 mg/kg, 100% with 0.1 mg/kg;% of responders who relapsed by day 14: 30% with 1.0 mg/kg, 50% with 0.5 mg/kg, 80% with 0.1 mg/kg). LIMITATIONS: The sample size was small. No MADRS measurements at day one post-infusion. The study was not powered to assess differences in relapse prevention between different doses of ketamine. CONCLUSION: Time to relapse after successful treatment with a single infusion of ketamine appears to follow a dose-response relationship, where higher dosage leads to increased time to relapse.
Authors: Jaskaran B Singh; Maggie Fedgchin; Ella J Daly; Peter De Boer; Kimberly Cooper; Pilar Lim; Christine Pinter; James W Murrough; Gerard Sanacora; Richard C Shelton; Benji Kurian; Andrew Winokur; Maurizio Fava; Husseini Manji; Wayne C Drevets; Luc Van Nueten Journal: Am J Psychiatry Date: 2016-04-08 Impact factor: 18.112
Authors: Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji Journal: Arch Gen Psychiatry Date: 2006-08
Authors: Ella J Daly; Jaskaran B Singh; Maggie Fedgchin; Kimberly Cooper; Pilar Lim; Richard C Shelton; Michael E Thase; Andrew Winokur; Luc Van Nueten; Husseini Manji; Wayne C Drevets Journal: JAMA Psychiatry Date: 2018-02-01 Impact factor: 21.596
Authors: Maurizio Fava; Marlene P Freeman; Martina Flynn; Heidi Judge; Bettina B Hoeppner; Cristina Cusin; Dawn F Ionescu; Sanjay J Mathew; Lee C Chang; Dan V Iosifescu; James Murrough; Charles Debattista; Alan F Schatzberg; Madhukar H Trivedi; Manish K Jha; Gerard Sanacora; Samuel T Wilkinson; George I Papakostas Journal: Mol Psychiatry Date: 2018-10-03 Impact factor: 15.992
Authors: Rong-Jian Liu; Manabu Fuchikami; Jason M Dwyer; Ashley E Lepack; Ronald S Duman; George K Aghajanian Journal: Neuropsychopharmacology Date: 2013-05-17 Impact factor: 7.853
Authors: Roxanne Gaspersz; Femke Lamers; Justine M Kent; Aartjan T F Beekman; Johannes H Smit; Albert M van Hemert; Robert A Schoevers; Brenda W J H Penninx Journal: J Clin Psychiatry Date: 2017-02 Impact factor: 4.384
Authors: Andrea Cipriani; Toshi A Furukawa; Georgia Salanti; Anna Chaimani; Lauren Z Atkinson; Yusuke Ogawa; Stefan Leucht; Henricus G Ruhe; Erick H Turner; Julian P T Higgins; Matthias Egger; Nozomi Takeshima; Yu Hayasaka; Hissei Imai; Kiyomi Shinohara; Aran Tajika; John P A Ioannidis; John R Geddes Journal: Lancet Date: 2018-02-21 Impact factor: 79.321
Authors: Ashley A Conley; Amber E Q Norwood; Thomas C Hatvany; James D Griffith; Kathryn E Barber Journal: Psychopharmacology (Berl) Date: 2021-03-31 Impact factor: 4.530
Authors: Susan Ling; Felicia Ceban; Leanna M W Lui; Yena Lee; Kayla M Teopiz; Nelson B Rodrigues; Orly Lipsitz; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Kangguang Lin; Roger Ho; Joshua D Rosenblat; David Castle; Roger S McIntyre Journal: CNS Drugs Date: 2021-11-17 Impact factor: 5.749
Authors: Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam Journal: Can J Psychiatry Date: 2020-11-11 Impact factor: 4.356
Authors: Natalie Gukasyan; Alan K Davis; Frederick S Barrett; Mary P Cosimano; Nathan D Sepeda; Matthew W Johnson; Roland R Griffiths Journal: J Psychopharmacol Date: 2022-02 Impact factor: 4.153
Authors: Anna Feeney; Rebecca S Hock; Marlene P Freeman; Martina Flynn; Bettina Hoeppner; Dan V Iosifescu; Madhukar H Trivedi; Gerard Sanacora; Sanjay J Mathew; Charles Debattista; Dawn F Ionescu; Maurizio Fava; George I Papakostas Journal: Eur Neuropsychopharmacol Date: 2021-06-03 Impact factor: 5.415